• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CDKN2A 在 9 号染色体上的缺失具有较差的临床预后,并促进肺癌的进展。

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression.

机构信息

Department of Respiratory and Critical Care Medicine, The 900th Hospital of Joint Logistic Support Force, Fuzhou, Fujian, China.

Department of Thoracic Surgery, The 900th Hospital of Joint Logistic Support Force, Fuzhou, Fujian, China.

出版信息

Mol Genet Genomic Med. 2020 Dec;8(12):e1521. doi: 10.1002/mgg3.1521. Epub 2020 Nov 6.

DOI:10.1002/mgg3.1521
PMID:33155773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7767555/
Abstract

OBJECTIVE

This study aimed to identify critical genes involved in the tumor biology of lung cancer via datamining of The Cancer Genome Atlas (TCGA) with special focus on gene copy number variation.

METHODS

Genomic deletion and amplification were analyzed with cBioportal online tools. Relative expression of Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) was analyzed by both real-time polymerase chain reaction (PCR) and Western blot. The abundance of methylthioadenosine phosphorylase (MTAP) and epithelial-mesenchymal transition markers were analyzed by real-time PCR. Cell proliferation was determined by cell counting kit-8 method and cell viability was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cell migration and invasion were measured with transwell chamber assay, and migrative capacity was further evaluated by wound healing assay.

RESULTS

We found the frequent loss of CDKN2A was associated with its downregulation in lung cancer, and siRNA-mediated CDNKN2A knockdown significantly stimulated cell proliferation, invasion, and migration. Mechanistically, we unraveled that MTAP, which was positively correlated with CDKN2A, predominantly mediated the antitumoral function of CDKN2A in lung cancer.

CONCLUSION

Our study consolidated the involvement of CDKN2A-MTAP signaling in the context of lung cancer.

摘要

目的

本研究通过对癌症基因组图谱(TCGA)的数据挖掘,特别关注基因拷贝数变异,旨在确定与肺癌肿瘤生物学相关的关键基因。

方法

利用 cBioportal 在线工具分析基因组缺失和扩增。通过实时聚合酶链反应(PCR)和 Western blot 分析细胞周期蛋白依赖性激酶抑制剂 2A(CDKN2A)的相对表达。通过实时 PCR 分析甲基硫腺苷磷酸化酶(MTAP)和上皮-间充质转化标志物的丰度。通过细胞计数试剂盒-8 法测定细胞增殖,通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐法测量细胞活力。通过 Transwell 室测定细胞迁移和侵袭,通过划痕愈合试验进一步评估迁移能力。

结果

我们发现 CDKN2A 的频繁缺失与其在肺癌中的下调有关,siRNA 介导的 CDNKN2A 敲低显著刺激细胞增殖、侵袭和迁移。从机制上讲,我们揭示了与 CDKN2A 呈正相关的 MTAP 主要介导了 CDKN2A 在肺癌中的抗肿瘤功能。

结论

我们的研究证实了 CDKN2A-MTAP 信号在肺癌中的参与。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/b0f10973d6b1/MGG3-8-e1521-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/0510373d737b/MGG3-8-e1521-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/840118d7134d/MGG3-8-e1521-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/c022aab89cbf/MGG3-8-e1521-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/c71e23aad2ee/MGG3-8-e1521-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/b0f10973d6b1/MGG3-8-e1521-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/0510373d737b/MGG3-8-e1521-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/840118d7134d/MGG3-8-e1521-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/c022aab89cbf/MGG3-8-e1521-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/c71e23aad2ee/MGG3-8-e1521-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8e/7767555/b0f10973d6b1/MGG3-8-e1521-g005.jpg

相似文献

1
Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression.CDKN2A 在 9 号染色体上的缺失具有较差的临床预后,并促进肺癌的进展。
Mol Genet Genomic Med. 2020 Dec;8(12):e1521. doi: 10.1002/mgg3.1521. Epub 2020 Nov 6.
2
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.对头颈部鳞状细胞癌中CDKN2B(p15INK4b)、CDKN2A(p14ARF、p16INK4a)和MTAP基因的基因结构精细定位缺失。
Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):409-15. doi: 10.1001/archotol.132.4.409.
3
Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.恶性胸膜间皮瘤中甲基硫代腺苷磷酸化酶(MTAP)蛋白表达与 MTAP 和 CDKN2A 拷贝数的相关性。
Histopathology. 2021 Jun;78(7):1032-1042. doi: 10.1111/his.14324. Epub 2021 Apr 14.
4
[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].[甲硫腺苷磷酸化酶和p16作为脑肿瘤中CDKN2A纯合缺失的替代诊断标志物]
Zhonghua Bing Li Xue Za Zhi. 2024 May 8;53(5):439-445. doi: 10.3760/cma.j.cn112151-20230815-00069.
5
Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.在胸腔积液细胞学标本中,甲基硫腺苷磷酸化酶和 BRCA 相关蛋白 1 的免疫组织化学在恶性间皮瘤的诊断中的作用。
Cancer Cytopathol. 2020 Feb;128(2):126-132. doi: 10.1002/cncy.22221. Epub 2019 Dec 10.
6
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.甲基硫腺苷磷酸化酶与 BAP1 免疫组化、CDKN2A 和 NF2 荧光原位杂交在区分反应性间皮增生与上皮样恶性间皮瘤中的应用。
Arch Pathol Lab Med. 2018 Dec;142(12):1549-1553. doi: 10.5858/arpa.2018-0273-OA. Epub 2018 Jul 30.
7
Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.中枢神经系统 WHO 分级 2 级和 3 级脑膜瘤中 MTAP 免疫组化与荧光原位杂交检测的 CDKN2A 状态的相关性及其与临床病理特征的关系:一项单中心队列研究。
J Neuropathol Exp Neurol. 2022 Jan 29;81(2):117-126. doi: 10.1093/jnen/nlab127.
8
Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.胃癌中甲基硫腺苷磷酸化酶通过纯合缺失下调。
Genes Chromosomes Cancer. 2011 Jun;50(6):421-33. doi: 10.1002/gcc.20867. Epub 2011 Mar 15.
9
CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.CDKN2A、CDKN2B和MTAP基因剂量可精确表征儿童急性淋巴细胞白血病中9p21单等位基因和双等位基因缺失。
Genes Chromosomes Cancer. 2003 May;37(1):44-57. doi: 10.1002/gcc.10188.
10
Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.Chr9p21 基因 CDKN2B(p15(INK4b))、CDKN2A(p16(INK4a)、p14(ARF))和 MTAP 在人动脉粥样硬化斑块中的表达。
Atherosclerosis. 2011 Feb;214(2):264-70. doi: 10.1016/j.atherosclerosis.2010.06.029. Epub 2010 Jun 23.

引用本文的文献

1
as a prognostic and diagnostic marker is a possible key contributor in hepatocellular carcinoma.作为一种预后和诊断标志物,可能是肝细胞癌的关键促成因素。
Transl Cancer Res. 2025 Apr 30;14(4):2303-2318. doi: 10.21037/tcr-24-1845. Epub 2025 Apr 15.
2
Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer.CDKN2A 表达增加在小细胞肺癌中的临床意义及潜在机制。
Clin Transl Oncol. 2024 Jun;26(6):1519-1531. doi: 10.1007/s12094-023-03376-2. Epub 2024 Jan 11.
3
Genetic susceptibility loci of lung cancer are associated with malignant risk of pulmonary nodules and improve malignancy diagnosis based on CEA levels.

本文引用的文献

1
Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.鉴定肺癌的风险基因座和多基因风险评分:一项针对中国人群的大规模前瞻性队列研究。
Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17.
2
KRAS-Mutant non-small cell lung cancer: From biology to therapy.KRAS 突变型非小细胞肺癌:从生物学到治疗。
Lung Cancer. 2018 Oct;124:53-64. doi: 10.1016/j.lungcan.2018.07.013. Epub 2018 Jul 19.
3
P16 gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.
肺癌的遗传易感性位点与肺结节的恶性风险相关,并基于癌胚抗原(CEA)水平改善恶性肿瘤的诊断。
Chin J Cancer Res. 2023 Oct 30;35(5):501-510. doi: 10.21147/j.issn.1000-9604.2023.05.07.
4
An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in .一例具有新型体细胞功能丧失突变的转化型脾弥漫性红髓小B细胞淋巴瘤的侵袭性病程 。 (原英文文本不完整,句末的“in.”后面缺少具体内容)
J Hematol. 2023 Jun;12(3):118-122. doi: 10.14740/jh1132. Epub 2023 Jun 30.
5
A predictive molecular signature consisting of lncRNAs associated with cellular senescence for the prognosis of lung adenocarcinoma.一个由与细胞衰老相关的 lncRNAs 组成的预测分子特征,用于肺腺癌的预后。
PLoS One. 2023 Jun 23;18(6):e0287132. doi: 10.1371/journal.pone.0287132. eCollection 2023.
6
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.联合使用 MDM2 和 MEK 抑制剂在同时存在致癌驱动和 MDM2 扩增的肺腺癌患者来源模型中具有疗效。
J Thorac Oncol. 2023 Sep;18(9):1165-1183. doi: 10.1016/j.jtho.2023.05.007. Epub 2023 May 13.
7
Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.基于铜死亡相关基因特征的肺腺癌两种分子亚型及新型预后模型的鉴定
Front Genet. 2023 Jan 12;13:1039983. doi: 10.3389/fgene.2022.1039983. eCollection 2022.
8
Exploration and validation of hub genes in lung adenocarcinoma based on bioinformatics analysis.基于生物信息学分析的肺腺癌枢纽基因探索与验证
Transl Cancer Res. 2022 Oct;11(10):3814-3826. doi: 10.21037/tcr-22-2225.
9
Construction and Validation of Early Warning Model of Lung Cancer Based on Machine Learning: A Retrospective Study.基于机器学习的肺癌早期预警模型的构建与验证:一项回顾性研究。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221136724. doi: 10.1177/15330338221136724.
10
Comprehensive analysis of the cuproptosis-related model to predict prognosis and indicate tumor immune infiltration in lung adenocarcinoma.对铜死亡相关模型进行综合分析,以预测肺腺癌的预后并指示肿瘤免疫浸润。
Front Oncol. 2022 Oct 20;12:935672. doi: 10.3389/fonc.2022.935672. eCollection 2022.
P16 基因启动子甲基化作为非小细胞肺癌诊断的生物标志物:一项更新的荟萃分析。
Thorac Cancer. 2018 Aug;9(8):1032-1040. doi: 10.1111/1759-7714.12783. Epub 2018 Jun 21.
4
Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells.MTAP的缺失和下调有助于食管鳞状癌细胞的运动性。
Onco Targets Ther. 2017 Dec 11;10:5855-5862. doi: 10.2147/OTT.S151953. eCollection 2017.
5
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.非小细胞肺癌患者罕见表皮生长因子受体(EGFR)突变的综合综述。
Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7.
6
Lung cancer.肺癌
Lancet. 2017 Sep 2;390(10098):928. doi: 10.1016/S0140-6736(17)32243-2.
7
Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.肺腺癌患者中p16/CDKN2A纯合缺失与表皮生长因子受体(EGFR)激活突变共存,意味着对EGFR酪氨酸激酶抑制剂(EGFR-TKIs)反应不佳。
Lung Cancer. 2016 Dec;102:101-107. doi: 10.1016/j.lungcan.2016.10.015. Epub 2016 Oct 31.
8
Lung cancer: current therapies and new targeted treatments.肺癌:当前疗法与新的靶向治疗。
Lancet. 2017 Jan 21;389(10066):299-311. doi: 10.1016/S0140-6736(16)30958-8. Epub 2016 Aug 27.
9
Lung cancer: despite advances, prevention is still best.肺癌:尽管取得了进展,但预防仍然是最佳选择。
Lancet. 2016 Aug 6;388(10044):533. doi: 10.1016/S0140-6736(16)31260-0.
10
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.MTAP/CDKN2A 缺失型癌症中的蛋氨酸代谢紊乱导致对 PRMT5 的依赖性。
Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.